Olaparib Phase 2 results posted; three diabetes labels updated; new myeloma CAR-T trial recruits

AstraZeneca's week spanned posted oncology results, regulatory label updates, a newly recruiting cell therapy trial, and two not-yet-recruiting observational studies.

• Results were posted for a Phase 2 study of olaparib (MK-7339) in previously treated advanced cancers positive for HRRm or HRD, sponsored by Merck Sharp & Dohme with AstraZeneca as collaborator. Enrollment reached 329 participants, with cohorts defined by tumors harboring BRCA1/2 mutations based on the Lynparza homologous recombination repair-homologous recombination deficiency assay, excluding breast and ovarian cancers, versus other homologous recombination deficiency positive or repair mutated categories.¹ Participants in Cohort 1 received oral olaparib, 300 mg twice daily continuously until documented disease progression or discontinuation criteria were met.¹
• The FDA approved three label supplements for AstraZeneca diabetes drugs, all with a submission status date of 2026-08-11: KOMBIGLYZE XR SUPPL 30, and XIGDUO XR SUPPL 28 and SUPPL 29.
• A new Phase 3 trial called "DURGA-5" is recruiting to test AZD0120, described as a BCMA/CD19 dual CAR T-cell product administered intravenously², as consolidation therapy in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The trial compares induction therapy followed by a single dose of AZD0120 against induction followed by ongoing standard treatment, with progression-free survival and MRD-negative complete response rate at 9 months as primary measures². The study plans to enroll 750 participants², with primary completion estimated for January 2029.
• A post-marketing surveillance study of durvalumab (IMFINZI) in Indian patients with resectable non-small cell lung cancer is not yet recruiting. It is a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site.³ A total of 78 patients will be enrolled³, with primary completion estimated for April 2030.
• A separate observational study evaluating structured hepatocellular carcinoma surveillance in Brazil is not yet recruiting, sponsored by the D'Or Institute for Research and Education with AstraZeneca as collaborator. Enrolled patients will get twice-yearly liver ultrasound scored under the US LI-RADS system along with blood alpha-fetoprotein checks as part of their normal care. Approximately 300 participants will be enrolled and followed for up to 36 months.⁴ Estimated start is September 2026.